Longeveron appoints Than Powell as interim CEO, Joshua Hare as chairman

Longeveron Inc. (NASDAQ: LGVN) announced leadership changes with Than Powell appointed as interim chief executive officer, effective immediately. Powell, who previously served as chief business officer and head of business development, succeeds Wa'el Hashad, who stepped down to pursue other opportunities.

The biotechnology company's board also appointed Dr. Joshua Hare, co-founder and chief science officer, as executive chairman of the board of directors. Hare previously served as board chair. The company plans to conduct a national search for a permanent CEO.

Powell brings over 25 years of pharmaceutical and biotech leadership experience from organizations including GSK and Eli Lilly. He previously led corporate development and strategy for Surescripts, which was acquired by TPG, and founded Epulate, a health technology company focused on transplant immunology.

Dr. Hare is a board-certified cardiologist with over 35 years of biomedical research experience and serves as inventor of Longeveron's patent portfolio. He holds degrees from the University of Pennsylvania and Johns Hopkins University School of Medicine.

Longeveron develops cellular therapies for pediatric and aging-related conditions, with its lead product laromestrocel currently in clinical trials for hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. The company's pivotal Phase 2b clinical trial for HLHS has achieved full enrollment, with top-line results anticipated in 2026.

The Miami-based company has received multiple FDA designations for its programs, including orphan drug designation, fast track designation, and rare pediatric disease designation for HLHS, and regenerative medicine advanced therapy designation for Alzheimer's disease.

You May Also Be Interested In

• Can-Fite receives Japanese patent allowance for Namodenoson obesity use
• HeartBeam shifts to licensing model, replaces CEO
• AstraZeneca's Datroway recommended for EU approval in breast cancer